SMFR News and Press, Sema4 Holdings Corp. From 08/15/22

The following slide deck was published by Sema4 Holdings Corp. in conjunction with their 2022 Q2 earnings call. For further details see: Sema4 Holdings Corp. 2022 Q2 - Results - Earnings Call Presentation

Sema4 press release ( NASDAQ: SMFR ): Q2 GAAP EPS of -$0.25 (vs. -$41.94 Y/Y). Revenue of $36.2M (-23.0% Y/Y). FY22 revenue expected to be in the range of $245M - $255M, vs. consensus of $305.59M). 2H revenue is expected to be in the range of $154M - $164M. ...

Founder Eric Schadt steps down from the organization , including his role as President & Chief R&D Officer Matthew Davis named Chief Technology & Product Officer to further drive t he company’s mission to unlock insights from data, leading to h...

New management team implements significant restructuring to focus on profitable growth, efficiency, and scale 19% pro forma 1 volume growth vs. 2Q 2021 Sema4 to host a conference call today at 4:30 p.m. ET STAMFORD, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE)...

Sema4 ( NASDAQ: SMFR ) is scheduled to announce Q2 earnings results on Monday, August 15th, after market close. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $67.55M (+44.2% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward r...

STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the second quarter of 2022 after the market close on Monday, August 15, 2022. On the same ...

Big data and machine learning are booming also in healthcare, where it enables precision medicine and population health platform services. Sema4 Holdings has amassed huge amounts of medical data and a sophisticated platform in order to extract valuable insight from these for health sy...

Trevi Therapeutics ( TRVI ) +36% reports positive results from the Ph2b/3 PRISM trial of Haduvio in the treatment of Prurigo nodularis. Catalyst Biosciences CBIO +26% plans to distribute $65M cash to stockholders. 2U TWOU +18% as Byju's reportedly mak...

Sema4 (NASDAQ:SMFR) announced its CFO, Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO.  Mr. Ro will provide consulting services...

Appoints Richard Miao, Sema4’s Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical ...